


Serial No. 10/521,538

Atty. Docket No. LeA 35 926

Amended Claims (Attorney Docket No. Le 35 926)


1. (Currently amended) A compound of the formula



in which

R^1 is C_6 - C_{10} -aryl or 5- to 10-membered heteroaryl which are optionally substituted by radicals selected from the group of halogen, cyano, C_1 - C_6 -alkoxy, C_1 - C_6 -alkoxycarbonyl, trifluoromethyl, 2,2,2-trifluoroethyl, trifluoromethoxy, C_1 - C_4 -alkyl and C_3 - C_8 -cycloalkyl, where C_1 - C_4 -alkyl is optionally substituted by hydroxy,

or a group of the formula



or

4- to 12-membered heterocyclyl which is bonded via a nitrogen atom and which is optionally substituted by radicals selected from the group of $-NHR^2$, halogen, C_1 - C_6 -alkoxycarbonyl, C_1 - C_6 -alkoxy, C_1 - C_6 -alkyl and oxo, where C_1 - C_6 -alkyl is optionally substituted by hydroxy, and

 R^2 is C_1 - C_4 -alkyl,

or

C_4 - C_8 -cycloalkyl which is substituted in the position adjacent to the point of attachment by oxo, and which is optionally substituted by C_1 - C_4 -alkyl,

and the or a salt salts, solvates and/or solvates of the salts thereof.


Serial No. 10/521,538

Atty. Docket No. LeA 35 926

2. (Currently amended) The compound as claimed in claim 1, where

R¹ is phenyl or 5- to 6-membered heteroaryl, which are optionally substituted by radicals selected from the group of fluorine, chlorine, cyano, C₁-C₃-alkoxycarbonyl, C₁-C₃-alkoxy, trifluoromethyl, 2,2,2-trifluoroethyl, trifluoromethoxy, C₁-C₃-alkyl and C₃-C₅-cycloalkyl, where C₁-C₃-alkyl is optionally substituted by hydroxy,

or a group of the formula



or

4- to 12-membered heterocycll which is bonded via a nitrogen atom and which is optionally substituted by radicals selected from the group of -NHR², fluorine, chlorine, C₁-C₃-alkyl, C₁-C₃-alkoxycarbonyl, C₁-C₃-alkoxy and oxo, where C₁-C₃-alkyl is optionally substituted by hydroxy,
and

R² is C₁-C₃-alkyl,

or

cyclohexyl which is substituted in the position adjacent to the point of attachment by oxo, and which is optionally substituted by C₁-C₂-alkyl,

and the or a salt ~~salt, solvates and/or solvates of the salts~~ thereof.


3. (Currently amended) The compound as claimed in claim 1 or 2, where

R¹ is phenyl or pyridyl, pyrazolyl, isoxazolyl, which are optionally substituted by radicals selected from the group of fluorine, chlorine, cyano, methoxy, methoxycarbonyl, ethoxycarbonyl, trifluoromethyl, 2,2,2-trifluoroethyl, trifluoromethoxy, methyl, cyclopropyl or hydroxymethyl,

or a group of the formula

Serial No. 10/521,538

Atty. Docket No. LcA 35 926



or

4- to 12-membered heterocycll which is bonded via a nitrogen atom and which is optionally substituted by radicals selected from the group of $-NHR^2$, fluorine, chlorine, C_1 - C_3 -alkyl, methoxy, ethoxy, hydroxymethyl and oxo, and

R^2 is methyl,


or

cyclohexyl which is substituted in the position adjacent to the point of attachment by oxo, and which is optionally substituted by methyl,

and the or a salt salts, solvates and/or solvates of the salts thereof.

4. (Currently amended) A process for preparing compounds of the formula (IV), (VI) and (VII), characterized in that either

[A] compounds of the formula



in which X is chlorine, bromine, iodine,

are reacted with a compound of the formula




in which

Serial No. 10/521,538


Atty. Docket No. LeA 35 926

R^3, R^4 together with the nitrogen atom to which they are bonded are a 4- to 12-membered heterocycl which is optionally substituted by radicals selected from the group of - NHR^2 , halogen, C_1 - C_6 -alkoxycarbonyl, C_1 - C_6 -alkoxy, C_1 - C_6 -alkyl and oxo, where C_1 - C_6 -alkyl is optionally substituted by - OR^5 , and R^2 has the meaning indicated in claim 1, R^5 is a hydroxy protective group in an inert solvent in the presence of a base and of a transition metal catalyst to give compounds of the formula



or

[B] compounds of the formula (II) are reacted with a compound of the formula




in which

R^6 is cycloalkyl, R^7 is hydrogen or R^6 and R^7 together with the CH_2CO group to which they are bonded are cycloalkyl which may be substituted by C_1 - C_6 -alkyl radicals, in an inert solvent in the presence of a base and of a transition metal catalyst to give compounds of the formula

Serial No. 10/521,538

Atty. Docket No. LeA 35 926



or

[C] compounds of the formula (II) are reacted with a compound of the formula



in which


A is $-B(OR^9)_2$ or $-Sn(C_1-C_6\text{-alkyl})_3$, where

R^9 is hydrogen, $C_1-C_6\text{-alkyl}$ or two radicals together form a $-CH_2CH_2-$ or $-(CH_3)_2C-$
 $C(CH_3)_2-$ bridge,

and

R^8 is $C_6-C_{10}\text{-aryl}$ or 5- to 10-membered heteroaryl which are optionally substituted by
 radicals selected from the group of halogen, cyano, $C_1-C_6\text{-alkoxy}$, $C_1-C_6\text{-alkoxycarbonyl}$,
 trifluoromethyl, 2,2,2-trifluoroethyl, trifluoromethoxy, $C_1-C_4\text{-alkyl}$ and $C_3-C_8\text{-cycloalkyl}$,
 where $C_1-C_4\text{-alkyl}$ is optionally substituted by hydroxy,


or a group of the formula



in an inert solvent in the presence of a base and of a transition metal catalyst to give compounds of the formula

Serial No. 10/521,538

Atty. Docket No. LeA 35 926



and the resulting compounds of the formula (IV), (VI) and (VIII) are optionally reacted with the appropriate (i) solvents and/or (ii) bases or acids to give the solvates, salt salts, or solvates of the salts thereof.

5. (Cancelled).
6. (Previously presented) A medicament comprising at least one of the compounds as claimed in claim 1 mixed together with at least one pharmaceutically acceptable, essentially nontoxic carrier or excipient.
7. (Cancelled).
8. (Currently amended) A method for the treatment ~~and/or prophylaxis~~ of disorders of perception, concentration, learning and/or memory comprising administering to a human or animal an effective amount of a compound of claim 1.
9. (Cancelled).
10. (Currently amended) A method for the treatment ~~and/or prophylaxis~~ of disorders of perception, concentration, learning and/or memory diseases comprising administering to a human or animal an effective amount of a medicament of claim 6.
11. (Currently amended) A method for controlling disorders of perception, concentration, learning and/or memory in humans or animals comprising administering to a human or animal an effective amount of a compound of claim 1.
12. (Currently amended) The method process of claim 4, wherein X is bromine.